{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T08:30:06Z","timestamp":1779179406686,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,14]],"date-time":"2012-06-14T00:00:00Z","timestamp":1339632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1748-717x-7-88","type":"journal-article","created":{"date-parts":[[2012,6,25]],"date-time":"2012-06-25T14:34:40Z","timestamp":1340634880000},"source":"Crossref","is-referenced-by-count":13,"title":["High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy"],"prefix":"10.1186","volume":"7","author":[{"given":"Ingeborg","family":"Fraunholz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claus","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luitpold","family":"Distel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marget","family":"Rave-Fr\u00e4nk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Kohler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franz","family":"R\u00f6del","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,14]]},"reference":[{"key":"591_CR1","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nm0897-917","volume":"3","author":"G Ambrosini","year":"1997","unstructured":"Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997, 3: 917-921. 10.1038\/nm0897-917","journal-title":"Nat Med"},{"key":"591_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1042\/BJ20100814","volume":"430","author":"DC Altieri","year":"2010","unstructured":"Altieri DC: Survivin and IAP proteins in cell-death mechanisms. Biochem J 2010, 430: 199-205. 10.1042\/BJ20100814","journal-title":"Biochem J"},{"key":"591_CR3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nrc2293","volume":"8","author":"DC Altieri","year":"2008","unstructured":"Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8: 61-70. 10.1038\/nrc2293","journal-title":"Nat Rev Cancer"},{"key":"591_CR4","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrc968","volume":"3","author":"DC Altieri","year":"2003","unstructured":"Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003, 3: 46-54. 10.1038\/nrc968","journal-title":"Nat Rev Cancer"},{"key":"591_CR5","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00595-010-4390-1","volume":"41","author":"K Miura","year":"2011","unstructured":"Miura K, Fujibuchi W, Ishida K, Naitoh T, Ogawa H, Ando T, Yazaki N, Watanabe K, Haneda S, Shibata C, Sasaki I: Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today 2011, 41: 175-182. 10.1007\/s00595-010-4390-1","journal-title":"Surg Today"},{"key":"591_CR6","doi-asserted-by":"publisher","first-page":"5000","DOI":"10.1158\/1078-0432.CCR-08-0746","volume":"14","author":"AC Mita","year":"2008","unstructured":"Mita AC, Mita MM, Nawrocki ST, Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14: 5000-5005. 10.1158\/1078-0432.CCR-08-0746","journal-title":"Clin Cancer Res"},{"key":"591_CR7","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/j.ijrobp.2008.10.063","volume":"74","author":"C Weiss","year":"2009","unstructured":"Weiss C, von R\u00f6mer F, Capalbo G, Ott OJ, Wittlinger M, Krause SF, Sauer R, R\u00f6del C, R\u00f6del F: Survivin expression as a predictive marker for local control in patients with high-risk T1 bladder cancer treated with transurethral resection and radiochemotherapy. Int J Radiat Oncol Biol Phys 2009, 74: 1455-1460. 10.1016\/j.ijrobp.2008.10.063","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"591_CR8","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00066-002-1003-y","volume":"178","author":"F R\u00f6del","year":"2002","unstructured":"R\u00f6del F, Hoffmann J, Grabenbauer GG, Papadopoulos T, Weiss C, Gunther K, Schick C, Sauer R, R\u00f6del C: High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease-free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 2002, 178: 426-435. 10.1007\/s00066-002-1003-y","journal-title":"Strahlenther Onkol"},{"key":"591_CR9","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.ijrobp.2008.06.1489","volume":"73","author":"M Zhang","year":"2009","unstructured":"Zhang M, Ho A, Hammond EH, Suzuki Y, Bermudez RS, Lee RJ, Pilepich M, Shipley WU, Sandler H, Khor LY, et al.: Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. Int J Radiat Oncol Biol Phys 2009, 73: 1033-1042. 10.1016\/j.ijrobp.2008.06.1489","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"591_CR10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.ctrv.2009.05.003","volume":"35","author":"BM Ryan","year":"2009","unstructured":"Ryan BM, O\u2019Donovan N, Duffy MJ: Survivin: a new target for anti-cancer therapy. Cancer Treat Rev 2009, 35: 553-562. 10.1016\/j.ctrv.2009.05.003","journal-title":"Cancer Treat Rev"},{"key":"591_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.drudis.2011.04.001","volume":"16","author":"JR Kanwar","year":"2011","unstructured":"Kanwar JR, Kamalapuram SK, Kanwar RK: Targeting survivin in cancer: the cell-signalling perspective. Drug Discov Today 2011, 16: 485-494. 10.1016\/j.drudis.2011.04.001","journal-title":"Drug Discov Today"},{"key":"591_CR12","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/092986711794088362","volume":"18","author":"F R\u00f6del","year":"2011","unstructured":"R\u00f6del F, Reichert S, Sprenger T, Gaipl US, Mirsch J, Liersch T, Fulda S, R\u00f6del C: The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr Med Chem 2011, 18: 191-199. 10.2174\/092986711794088362","journal-title":"Curr Med Chem"},{"key":"591_CR13","doi-asserted-by":"publisher","first-page":"5198","DOI":"10.1200\/JCO.2008.17.2064","volume":"26","author":"AW Tolcher","year":"2008","unstructured":"Tolcher AW, Mita A, Lewis LD, Garrett CR, Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P, et al.: Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008, 26: 5198-5203. 10.1200\/JCO.2008.17.2064","journal-title":"J Clin Oncol"},{"key":"591_CR14","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.1158\/1078-0432.CCR-10-1932","volume":"16","author":"DC Talbot","year":"2010","unstructured":"Talbot DC, Ranson M, Davies J, Lahn M, Callies S, Andre V, Kadam S, Burgess M, Slapak C, Olsen AL, et al.: Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clin Cancer Res 2010, 16: 6150-6158. 10.1158\/1078-0432.CCR-10-1932","journal-title":"Clin Cancer Res"},{"key":"591_CR15","first-page":"6489","volume":"9","author":"AS Allal","year":"2003","unstructured":"Allal AS, Waelchli L, Brundler MA: Prognostic value of apoptosis-regulating protein expression in anal squamous cell carcinoma. Clin Cancer Res 2003, 9: 6489-6496.","journal-title":"Clin Cancer Res"},{"key":"591_CR16","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1007\/s10620-009-0812-6","volume":"55","author":"JA Ajani","year":"2010","unstructured":"Ajani JA, Wang X, Izzo JG, Crane CH, Eng C, Skibber JM, Das P, Rashid A: Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 2010, 55: 1098-1105. 10.1007\/s10620-009-0812-6","journal-title":"Dig Dis Sci"},{"key":"591_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00384-004-0651-z","volume":"20","author":"AS Allal","year":"2005","unstructured":"Allal AS, Brundler MA, Gervaz P: Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus. Int J Colorectal Dis 2005, 20: 161-164. 10.1007\/s00384-004-0651-z","journal-title":"Int J Colorectal Dis"},{"key":"591_CR18","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/bjc.1998.222","volume":"77","author":"AS Allal","year":"1998","unstructured":"Allal AS, Alonso-Pentzke L, Remadi S: Apparent lack of prognostic value of MIB-1 index in anal carcinomas treated by radiotherapy. Br J Cancer 1998, 77: 1333-1336. 10.1038\/bjc.1998.222","journal-title":"Br J Cancer"},{"key":"591_CR19","first-page":"471","volume":"19","author":"M Indinnimeo","year":"2000","unstructured":"Indinnimeo M, Cicchini C, Stazi A, Limiti MR, Ghini C, Mingazzini P, Vecchione A: Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res 2000, 19: 471-475.","journal-title":"J Exp Clin Cancer Res"},{"key":"591_CR20","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1158\/1078-0432.CCR-05-2434","volume":"12","author":"GG Grabenbauer","year":"2006","unstructured":"Grabenbauer GG, Lahmer G, Distel L, Niedobitek G: Tumor-infiltrating cytotoxic T cells but not regulatory T cells predict outcome in anal squamous cell carcinoma. Clin Cancer Res 2006, 12: 3355-3360. 10.1158\/1078-0432.CCR-05-2434","journal-title":"Clin Cancer Res"},{"key":"591_CR21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1159\/000090747","volume":"29","author":"BJ Cummings","year":"2006","unstructured":"Cummings BJ: Metastatic anal cancer: the search for cure. Onkologie 2006, 29: 5-6. 10.1159\/000090747","journal-title":"Onkologie"},{"key":"591_CR22","first-page":"10","volume":"2","author":"P Das","year":"2008","unstructured":"Das P, Crane CH, Eng C, Ajani JA: Prognostic factors for squamous cell cancer of the anal canal. Gastrointest Cancer Res 2008, 2: 10-14.","journal-title":"Gastrointest Cancer Res"},{"key":"591_CR23","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1038\/sj.bjc.6605984","volume":"103","author":"T Lampejo","year":"2010","unstructured":"Lampejo T, Kavanagh D, Clark J, Goldin R, Osborn M, Ziprin P, Cleator S: Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Br J Cancer 2010, 103: 1858-1869. 10.1038\/sj.bjc.6605984","journal-title":"Br J Cancer"},{"key":"591_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell 2011, 144: 646-674. 10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"591_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s13277-011-0217-y","volume":"32","author":"H Zhu","year":"2011","unstructured":"Zhu H, Wang Q, Hu C, Zhang W, Quan L, Liu M, Xu N, Xiao Z: High expression of survivin predicts poor prognosis in esophageal squamous cell carcinoma following radiotherapy. Tumour Biol 2011, 32: 1147-1153. 10.1007\/s13277-011-0217-y","journal-title":"Tumour Biol"},{"key":"591_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ygyno.2006.07.011","volume":"104","author":"M Bache","year":"2007","unstructured":"Bache M, Holzapfel D, Kappler M, Holzhausen HJ, Taubert H, Dunst J, Hansgen G: Survivin protein expression and hypoxia in advanced cervical carcinoma of patients treated by radiotherapy. Gynecol Oncol 2007, 104: 139-144. 10.1016\/j.ygyno.2006.07.011","journal-title":"Gynecol Oncol"},{"key":"591_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/00129039-200403000-00009","volume":"12","author":"L Kren","year":"2004","unstructured":"Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, Kaur P, Ross JS: Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004, 12: 44-49.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"591_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/00016480510043963","volume":"125","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Huang D, Yu G: Survivin expression and its relationship with apoptosis and prognosis in nasal and paranasal sinus carcinomas. Acta Otolaryngol 2005, 125: 1345-1350. 10.1080\/00016480510043963","journal-title":"Acta Otolaryngol"},{"key":"591_CR29","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2217\/14622416.9.6.681","volume":"9","author":"D Vallbohmer","year":"2008","unstructured":"Vallbohmer D, Kuhn E, Warnecke-Eberz U, Brabender J, Hoffmann AC, Metzger R, Baldus SE, Drebber U, Hoelscher AH, Schneider PM: Failure in downregulation of intratumoral survivin expression following neoadjuvant chemoradiation in esophageal cancer. Pharmacogenomics 2008, 9: 681-690. 10.2217\/14622416.9.6.681","journal-title":"Pharmacogenomics"},{"key":"591_CR30","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-10-2592","volume":"17","author":"T Sprenger","year":"2011","unstructured":"Sprenger T, R\u00f6del F, Beissbarth T, Conradi LC, Rothe H, Homayounfar K, Wolff HA, Ghadimi BM, Yildirim M, Becker H, et al.: Failure of downregulation of survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 2011, 17: 1623-1631. 10.1158\/1078-0432.CCR-10-2592","journal-title":"Clin Cancer Res"},{"key":"591_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ccr.2009.11.021","volume":"17","author":"S Mehrotra","year":"2010","unstructured":"Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC: IAP regulation of metastasis. Cancer Cell 2010, 17: 53-64. 10.1016\/j.ccr.2009.11.021","journal-title":"Cancer Cell"},{"key":"591_CR32","volume-title":"J Surg Oncol","author":"XY Chu","year":"2011","unstructured":"Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB: Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol 2011."},{"key":"591_CR33","doi-asserted-by":"publisher","first-page":"7494","DOI":"10.1038\/sj.onc.1208049","volume":"23","author":"A Chakravarti","year":"2004","unstructured":"Chakravarti A, Zhai GG, Zhang M, Malhotra R, Latham DE, Delaney MA, Robe P, Nestler U, Song Q, Loeffler J: Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 2004, 23: 7494-7506. 10.1038\/sj.onc.1208049","journal-title":"Oncogene"},{"key":"591_CR34","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0360-3016(02)04618-7","volume":"55","author":"C R\u00f6del","year":"2003","unstructured":"R\u00f6del C, Haas J, Groth A, Grabenbauer GG, Sauer R, R\u00f6del F: Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003, 55: 1341-1347. 10.1016\/S0360-3016(02)04618-7","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"591_CR35","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/j.1349-7006.2000.tb00906.x","volume":"91","author":"K Asanuma","year":"2000","unstructured":"Asanuma K, Moriai R, Yajima T, Yagihashi A, Yamada M, Kobayashi D, Watanabe N: Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 2000, 91: 1204-1209. 10.1111\/j.1349-7006.2000.tb00906.x","journal-title":"Jpn J Cancer Res"},{"key":"591_CR36","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.1158\/0008-5472.CAN-04-3028","volume":"65","author":"F R\u00f6del","year":"2005","unstructured":"R\u00f6del F, Hoffmann J, Distel L, Herrmann M, Noisternig T, Papadopoulos T, Sauer R, Rodel C: Survivin as a radioresistance factor, and prognostic and therapeutic target for radiotherapy in rectal cancer. Cancer Res 2005, 65: 4881-4887. 10.1158\/0008-5472.CAN-04-3028","journal-title":"Cancer Res"},{"key":"591_CR37","doi-asserted-by":"publisher","first-page":"6496","DOI":"10.1158\/1078-0432.CCR-08-0468","volume":"14","author":"T Iwasa","year":"2008","unstructured":"Iwasa T, Okamoto I, Suzuki M, Nakahara T, Yamanaka K, Hatashita E, Yamada Y, Fukuoka M, Ono K, Nakagawa K: Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008, 14: 6496-6504. 10.1158\/1078-0432.CCR-08-0468","journal-title":"Clin Cancer Res"},{"key":"591_CR38","doi-asserted-by":"publisher","first-page":"3872","DOI":"10.1158\/1078-0432.CCR-08-1946","volume":"15","author":"T Satoh","year":"2009","unstructured":"Satoh T, Okamoto I, Miyazaki M, Morinaga R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y, et al.: Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009, 15: 3872-3880. 10.1158\/1078-0432.CCR-08-1946","journal-title":"Clin Cancer Res"},{"key":"591_CR39","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00280-010-1506-7","volume":"68","author":"M Tanioka","year":"2011","unstructured":"Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T: Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011, 68: 505-511. 10.1007\/s00280-010-1506-7","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1748-717X-7-88.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1748-717X-7-88\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1748-717X-7-88.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T05:12:08Z","timestamp":1548220328000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/1748-717X-7-88"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,14]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["591"],"URL":"https:\/\/doi.org\/10.1186\/1748-717x-7-88","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,14]]},"article-number":"88"}}